Event-Driven Stocks

Bristol-Myers Squibb

BMYNYSE

Other · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 3 good● 2 warningdetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$48.19B$48.30B$45.01B$46.16B$46.38B$42.52B
Operating income——————
Net income$7.05B−$8.95B$8.03B$6.33B$6.99B−$9.02B
Total assets$90.04B$92.60B$95.16B$96.82B$109.31B$118.48B
Total liabilities$71.53B$76.22B$65.67B$65.70B$73.31B$80.60B
Equity$18.47B$16.34B$29.43B$31.06B$35.95B$37.82B
EPS (diluted)$3.46$-4.41$3.86$2.95$3.12$-3.99
Shares out.2.03B2.02B2.10B2.18B2.24B2.26B

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
—
Net margin
14.6%
Return on equity
38.2%
Return on assets
7.8%
Return on capital (ROCE)
—
Liabilities / assets
79.4%
Debt / equity
3.87×
Book value / share
$9.10
Revenue growth (YoY)
−0.2%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Accruals / assets
−7.9%clean
Beneish M-Score
-2.69normal
Piotroski F-Score
7/8strong

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
60
/ 100
Profitability 100Growth 0Catalyst 33Earnings quality 100Financial strength 67

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 2 warning● 3 good
  • Revenue declined year-over-year
  • High leverage (liabilities > 70% of assets)
  • Strong return on equity (>15%)
  • Positive operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

FDA-approved drugs

openFDA · most recent
  • OPDUALAGMar 18, 2022
  • IDHIFAAug 1, 2017
  • EMPLICITINov 30, 2015
  • OPDIVOMar 4, 2015
  • ELIQUISDec 28, 2012
  • NULOJIXJun 15, 2011
  • YERVOYMar 25, 2011
  • SPRYCELJun 28, 2006

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202636.7M3.5+17.2%
Apr 30, 202631.3M3.2-3.3%
Apr 15, 202632.4M3.4+2.8%
Mar 31, 202631.5M2.0+5.5%
Mar 13, 202629.9M2.5-10.7%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Corporate family

Spin-offs from Bristol-Myers Squibb (1)

From the spin-off filings we track. Follow a company to walk its own history.

Event-driven situations (10)